Compare Alibaba Group (BABA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alibaba Group vs Twist Bioscience Corp — how do they compare? Alibaba Group trades at $124.7 (market cap $309.65B), while Twist Bioscience Corp trades at $123.12 (market cap $7.82B). The key difference: Alibaba Group is far larger — about 39.6× Twist Bioscience Corp's market cap, and Alibaba Group pays a 0.79% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BABA | TWST | |
|---|---|---|
Market Cap | $309.65B | $7.82B |
Volume | 18,069,938 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $189.34 | $124.88 |
52-Week Low | $94.83 | $24.16 |
Enterprise Value | $304.43B | $7.75B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.
Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
